Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

SOLTI

Status and phase: Completed; Phase 2

Conditions: Breast Cancer

Treatments: Drug: Eribulin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01669252

SOLTI-1007

2012-000394-23 (EudraCT Number)

Details and patient eligibility

About

This is a prospective, non-randomized, open-label, multicenter, single-arm exploratory pharmacogenomic study of single agent eribulin as neoadjuvant therapy in patients with operable Stage III HER2 non-overexpressing breast cancer.

Enrollment: 163 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent, specifically highlighting the molecular characterization of tumor and genomic samples

• Age ≥18 years

• Histologically confirmed invasive breast carcinoma, with all of the following characteristics:

  • Primary tumor ≥2cm in largest diameter (cT1-3)
  • cN0-1
  • No evidence of distant metastasis (M0)

• Breast cancer (BC) eligible for primary surgery

• Available pre-treatment core (Tru-cut) biopsy or possibility of performing one

• HER2-negative BC (as per local assessment), defined as either of the following:

  • 0-1+ expression by IHC
  • 2+ expression by IHC and in situ hybridization (FISH/CISH) without HER2 gene amplification (<4 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to Cr17 signals] of <1.8)
  • Is situ hybridization (FISH/CISH) without HER2 gene amplification, independently of IHC

• Known hormone receptor (ER/PgR) status (as per local assessment) or the possibility of performing the tests

• Known percentage of hormone receptor (ER/PgR) and Ki67-positive tumor cells (as per local assessment), or possibility of performing the tests

• In the case of a multifocal tumor, the largest lesion must be ≥2 cm and designated the "target" lesion for all subsequent tumor evaluations and HER2-negative status must be documented in all the tumor foci

• ECOG performance status of 0 or 1

• Laboratory values as follows:

  • Absolute neutrophil count (ANC) ≥1.5 x 109/L
  • Platelets count ≥100 x 109/L
  • Hemoglobin ≥9 g/dL
  • Serum bilirubin ≤1.5 time the upper limit of normal (ULN)
  • Alanine aminotransferase and aspartate aminotransferase (AST) ≤2.5 x ULN
  • Alkaline phosphatase ≤2.5 x ULN
  • Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/m

• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

• Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol

• Availability of genomic DNA (via whole blood)

Exclusion criteria

• Any prior treatment for primary invasive BC
• Metastatic, locally advanced or inflammatory (i.e., Stage III-IV) BC
• Bilateral invasive BC
• Multicentric BC, defined as the presence of two or more foci of cancer in different quadrants of the same breast
• Pre-existing peripheral neuropathy of any grade
• Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg)
• Clinically significant (i.e., active) cardiovascular disease
• Long QT syndrome
• Concomitant use of inhibitors of hepatic transport proteins such as organic anion-transporting proteins, P-glycoprotein, multidrug resistant proteins etc
• Major medical conditions that might affect study participation (e.g., uncontrolled seizure disorder, uncontrolled pulmonary, renal or hepatic dysfunction, or uncontrolled infection)
• Other primary malignant tumors within the previous 5 years, except for adequately controlled limited basal cell carcinoma of the skin or carcinoma in situ of the cervix
• Known human immunodeficiency virus(HIV) infection or other active or serious infection requiring IV antibiotics at randomization
• Pregnancy or breastfeeding women
• Women of childbearing potential(<2 years after the last menstruation) not using effective, non-hormonal means of contraception during the study and for a period of 6 months following the last administration of study drug
• Administration of any live virus vaccine within 8 weeks preceding study entry
• Use of any investigational agent within 30 days of administration of the first dose of study drug or concurrent treatment on another clinical study
• Requirement for radiation therapy concurrent with study anticancer treatment
• Known hypersensitivity to any of the study drugs or excipients
• Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

163 participants in 1 patient group

Eribulin

Experimental group

Description:

1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.

Treatment:

Drug: Eribulin